MBP and chronic myelogenous leukemia, BCR-ABL1 positive: For CML-MBP, treatment approaches vary from the use of single-agent TKI to acute myeloid leukemia (AML)-like induction therapy + TKI, and there is no consensus frontline treatment recommendation [13, 15–17].